These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 17721093)

  • 1. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
    Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
    AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
    Torriani FJ; Ribeiro RM; Gilbert TL; Schrenk UM; Clauson M; Pacheco DM; Perelson AS
    J Infect Dis; 2003 Nov; 188(10):1498-507. PubMed ID: 14624375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
    Dahari H; Affonso de Araujo ES; Haagmans BL; Layden TJ; Cotler SJ; Barone AA; Neumann AU
    J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.
    D'Offizi G; Martini F; Rozera G; Abbate I; Capobianchi MR; Narciso P; Dianzani F
    AIDS; 2008 Jan; 22(2):321. PubMed ID: 18097242
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
    Rozenberg L; Haagmans BL; Neumann AU; Chen G; McLaughlin M; Levy-Drummer RS; Masur H; Dewar RL; Ferenci P; Silva M; Viola MS; Polis MA; Kottilil S
    AIDS; 2009 Nov; 23(18):2439-50. PubMed ID: 19898214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
    J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
    Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
    Talal AH; Ribeiro RM; Powers KA; Grace M; Cullen C; Hussain M; Markatou M; Perelson AS
    Hepatology; 2006 May; 43(5):943-53. PubMed ID: 16761329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
    Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
    Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
    Rivero-Juárez A; Lopez-Cortes LF; Camacho A; Torres-Cornejo A; Pineda JA; Marquez-Solero M; Caruz A; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A
    PLoS One; 2012; 7(11):e48959. PubMed ID: 23145040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
    Maor Y; Schapiro JM; Bashari D; Lurie Y; Safadi R; Segol O; Paritsky M; Rachlis Z; Avidan B; Bar-Meir S; Martinowitz U
    Haemophilia; 2008 Mar; 14(2):336-42. PubMed ID: 18205802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.